A Prospective Randomized Controlled Trial of Morphine versus Oxycodone for Cancer Pain: Genetic Determinants of Response to Opioids. - RCT Morphine vs Oxycodone: Genetics Study
- Conditions
- 10-30% of cancer patients have an unsuccessful outcome when given oral morphine because of intolerable side effects. Oxycodone is an alternative opioid which is commonly used as a second line opioid. No randomised controlled trials have yet been carried out directly comparing morphine versus oxycodone.
- Registration Number
- EUCTR2005-001660-31-GB
- Lead Sponsor
- The Royal Marsden Hospital NHS Foundation Trust
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients must have a clinical or histological diagnosis of cancer.
Patients whose pain is not controlled on Step 2 analgesics (as defined by the WHO analgesic ladder) who clinically require a strong opioid.
Patients must be over 18 years of age.
Patients must be able to give written informed consent.
Patients must be willing to undergo genetic screening
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Patients with renal failure (1.5x ULN). These patients should be treated with alfentanil as per palliative care guidelines.
Patients must not have been taking regular Step 3 analgesics in the last month.
Patients requiring parenteral administration of opioids.
Patients with predominantly neuropathic pain.
Patients with predominantly incident pain
Patients with a clearly defined history of intolerance to morphine or oxycodone.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method